Amani Therapeutics Raises $25M Series A to Advance Schizophrenia Treatment Candidate AM-01
Amani Therapeutics, a New York-based biotechnology company focused on developing treatments for serious neuropsychiatric disorders, has raised $25 million in Series A financing as it advances its lead clinical program targeting schizophrenia. The round marks the company’s official emergence from stealth and provides fresh capital to support the development of its flagship therapy, AM-01, which is designed as a fixed-dose combination treatment for complex psychiatric conditions.
The financing was led by RTW Investments, a healthcare-focused investment firm known for backing companies developing innovative therapies across cardiovascular, immunology, and rare disease areas. The participation of RTW underscores continued investor interest in neuroscience-focused drug development, particularly in areas with significant unmet medical need such as schizophrenia and other severe neuropsychiatric disorders.
According to company disclosures, Amani Therapeutics is building its pipeline around AM-01, a novel therapeutic approach that combines clozapine, a well-established antipsychotic, with a Phase 3–ready novel chemical entity licensed from AstraZeneca. The company holds worldwide rights to this in-licensed compound, positioning it to advance a differentiated treatment strategy aimed at improving outcomes for patients who often experience limited response or significant side effects from existing therapies.
The Series A funding is expected to support multiple stages of development, including ongoing research, clinical advancement of AM-01, and expansion of the company’s operational capabilities. The capital will also help Amani strengthen its clinical and executive leadership team as it prepares for later-stage trials and regulatory milestones. As part of its early buildout, the company has appointed experienced biotech executives to key roles, including leadership in operations and clinical development, to guide its transition from early-stage research to clinical execution.
Amani Therapeutics operates in the highly competitive neuroscience drug development sector, where biotech startups are increasingly leveraging established compounds in combination with novel mechanisms of action to address treatment-resistant conditions. The company’s strategy reflects a broader industry trend of repurposing and enhancing existing molecules to accelerate development timelines while improving therapeutic efficacy.
Investors have shown growing appetite for neuroscience-focused biotech ventures, particularly those targeting schizophrenia, depression, and other central nervous system disorders where innovation has historically lagged behind other therapeutic areas. Amani’s funding round places it among a wave of early-stage biotech companies that have recently attracted capital for programs addressing complex brain disorders with high unmet clinical demand.
With the completion of its Series A financing, Amani Therapeutics is positioned to advance AM-01 through the next stages of clinical validation. The company’s focus remains on demonstrating both safety and efficacy in neuropsychiatric populations that are often difficult to treat, while laying the groundwork for future regulatory engagement and potential commercialization pathways.
As the biotech landscape continues to evolve, Amani Therapeutics represents a growing category of neuroscience companies seeking to bridge established pharmacology with next-generation drug development strategies, supported by specialist investors such as RTW Investments who are increasingly active in the sector.
